A new implantable and non -hormonal male contraceptive known as Adam, showed effectiveness for at least 24 months in the first human tests (phase 1) performed in Australia, according to results released by the Biotechnology Contraline, responsible for the product.
Adam consists of a water soluble hydrogel which is implemented in the defender ducts – the channels that carry the sperm. The procedure is described as minimally invasive, lasting about ten minutes and using local anesthesia.
The gel acts as a physical barrier, preventing the passage of sperm and leading to azoospermia (absence of sperm in the ejaculated semen).
In initial studies with 25 participants, two men reached the 24 -month mark keeping azoospermia, starting from an initial average sperm count considered high.
Contraline reported that no serious adverse events related to treatment were recorded during this period and that Side Effects observed were consistent with those expected for procedures such as vasectomy without scalpel.
The company points out that hydrogel is designed to naturally degrade in the body after a certain period, which would allow the restoration of fertility and could make Adam a potentially reversible alternative to condoms and definitive vasectomy.
“Our goal was to create a two -year -old male contraceptive option, responding directly to consumer demand,” said Contraline’s medical director Alexander Pastuszak.
Important doubts about the initiative
The results were presented on Saturday (26) at the annual meeting of the American Urology Association. CONTRINE also announced having received Regulatory approval in Australia to start phase 2 of clinical trials, scheduled for the third quarter of 2025, which will have between 30 and 50 participants.
Although the initial results are seen as promising by experts in the field, such as researcher Richard Anderson of the University of Edinburgh, quoted by the British newspaper The Guardian, The initiative also arouses important doubts .
The main one is that the reversibility of the method in humans has not yet been proven in published studies. In addition, issues on the exact duration of the effect of a single implant and the possible long -term effects of blocking the vast ducts.
Adam is still considered an experimental device and No authorization for commercial use by regulatory agencies such as FDA, the regulatory agency of remedies and food from the United States.
Experts warn that More research is necessary To validate safety, long -term effectiveness and, especially, the reversibility of the implant, before it can be considered an established contraceptive option.
Male contraceptive pill goes into clinical tests for the first time
This content was originally published in male contraceptive by implantation advances in testing in Australia on the CNN Brazil website.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
